Long-Term Functional Outcomes and Quality of Life after Male Transobturator-Retrourethral Sling Surgery

Hernández-Hernández D.a· Navarro-Galmés M.A.b· Padilla-Fernández B.a,c· Hess-Medler S.Castro-Díaz D.M.a,c

Author affiliations

aDepartment of Urology, Hospital Universitario de Canarias, Tenerife, Spain
bDepartment of Urology, Hospital General de Granollers, Tenerife, Spain
cDepartamento de Cirugía, Universidad de La Laguna, Tenerife, Spain
dDepartamento de Psicología Clínica, Psicobiología y Metodología, Universidad de La Laguna, Tenerife, Spain

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent via DeepDyve Unlimited fulltext viewing of this article Organize, annotate and mark up articles Printing and downloading restrictions apply

Start free trial

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Abstract of Research Article

Received: September 05, 2022
Accepted: December 13, 2022
Published online: February 08, 2023

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 5

ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)

For additional information: https://www.karger.com/UIN

Abstract

Introduction: Post-prostatectomy urinary incontinence (PPUI) has an enormous impact in quality of life (QoL). Transobturator-rethrourethral sling (AdVanceTMXP sling) is a well-established treatment option although there is paucity of data on long-term outcomes. Our objective was to assess the long-term functional outcomes and QoL in a cohort of men undergoing AdVanceTMXP sling surgery. Methods: Retrospective observational study of men undergoing AdVanceTMXP sling in a tertiary referral institution from August 2013 to July 2020. 55 patients met the inclusion criteria, with a minimum follow-up of 12 months. Main outcomes were pre- and post-operative daily pad use and scoring in the ICIQ-SF questionnaire. Post-operative complications were assessed following the Clavien-Dindo classification system. QoL and satisfaction with the procedure were assessed through direct interview. Results: Mean number of pads prior to surgery was 3.1, and mean ICIQ-SF score was 13.5. After surgery, mean daily pads use went to 1.2, and mean ICIQ-SF dropped to 5. With a mean follow-up of 42.36 months, 21.8% patients did not use any pads/day and 76.4% achieved social continence (0–1 pad/day). We found no statistically significant differences in outcomes of patients with follow-up of <36 months, 36–48 months, and >48 months (p = 0.067). Conclusions: AdVanceTMXP sling implantation in men with PPUI improves urinary incontinence and QoL, and their results are sustained over time.

© 2023 S. Karger AG, Basel

References Nam RK, Herschorn S, Loblaw DA, Liu Y, Klotz LH, Carr LK, et al. Population based study of long-term rates of surgery for urinary incontinence after radical prostatectomy for prostate cancer. J Urol. 2012;188(2):502–6. Cho MC, Park JH, Jeong MS, Yi JS, Ku JH, Oh SJ, et al. Predictor of de novo urinary incontinence following holmium laser enucleation of the prostate. Neurourol Urodyn. 2011;30(7):1343–9. Garcia-Segui A, Angulo JC. Prospective study comparing laparoscopic and open adenomectomy: surgical and functional results. Actas Urol Esp. 2017;41(1):47–54. Buckley BS, Lapitan MCM, Glazener CM, MAPS Trial Group. The effect of urinary incontinence on health utility and health-related quality of life in men following prostate surgery. Neurourol Urodyn. 2012;31(4):465–9. Novara G, Ficarra V, Rosen RC, Artibani W, Costello A, Eastham JA, et al. Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy. Eur Urol. 2012;62(3):431–52. Ha YS, Yoo ES. Artificial urinary sphincter for postradical prostatectomy urinary incontinence - is it the best option? Int Neurourol J. 2019;23(4):265–76. Léon P, Chartier-Kastler E, Rouprêt M, Ambrogi V, Mozer P, Phé V. Long-term functional outcomes after artificial urinary sphincter implantation in men with stress urinary incontinence. BJU Int. 2015;115(6):951–7. Kumar A, Litt ER, Ballert KN, Nitti VW. Artificial urinary sphincter versus male sling for post-prostatectomy incontinence: what do patients choose? J Urol. 2009;181(3):1231–5. Rehder P, Gozzi C. Transobturator sling suspension for male urinary incontinence including post-radical prostatectomy. Eur Urol. 2007;52(3):860–6. Cornu JN, Batista Da Costa J, Henry N, Peyrat L, Beley S, Haab F. Comparative study of AdVance and AdVanceXP male slings in a tertiary reference center. Eur Urol. 2014;65(2):502–4. Bauer RM, Kretschmer A, Stief CG, Füllhase C. AdVance and AdVance XP slings for the treatment of post-prostatectomy incontinence. World J Urol. 2015;33(1):145–50. Hüsch T, Kretschmer A, Thomsen F, Kronlachner D, Kurosch M, Obaje A, et al. The AdVance and AdVanceXP male sling in urinary incontinence: is there a difference? World J Urol. 2018;36(10):1657–62. Davies TO, Bepple JL, McCammon KA. Urodynamic changes and initial results of the AdVance male sling. Urology. 2009;74(2):354–7. Soljanik I, Becker AJ, Stief CG, Gozzi C, Bauer RM. Urodynamic parameters after retrourethral transobturator male sling and their influence on outcome. Urology. 2011;78(3):708–12. Mumm JN, Klehr B, Rodler S, Kretschmer A, Vilsmaier T, Westhofen T, et al. Five-Year results of a prospective multicenter trial: AdVance XP for postprostatectomy-incontinence in patients with favorable prognostic factors. Urol Int. 2021;105(5–6):421–7. Ye H, Haab F, de Ridder D, Chauveau P, Becker A, Arano P, et al. Effectiveness and complications of the AMS AdVance™ male sling system for the treatment of stress urinary incontinence: a prospective multicenter study. Urology. 2018;120:197–204. Rehder P, Haab F, Cornu JN, Gozzi C, Bauer RM. Treatment of postprostatectomy male urinary incontinence with the transobturator retroluminal repositioning sling suspension: 3 years follow-up. Eur Urol. 2012;62(1):140–5. Zuckerman JM, Edwards B, Henderson K, Beydoun HA, McCammon KA. Extended outcomes in the treatment of male stress urinary incontinence with a transobturator sling. Urology. 2014;83(4):939–45. Li H, Gill BC, Nowacki AS, Montague DK, Angermeier KW, Wood HM, et al. Therapeutic durability of the male transobturator sling: midterm patient reported outcomes. J Urol. 2012;187(4):1331–5. Collado Serra A, Resel Folkersma L, Domínguez-Escrig JL, Gómez-Ferrer A, Rubio-Briones J, Solsona Narbón E. AdVance/AdVance XP transobturator male slings: preoperative degree of incontinence as predictor of surgical outcome. Urology. 2013;81(5):1034–9. Cornu JN, Sèbe P, Ciofu C, Peyrat L, Beley S, Tligui M, et al. The AdVance transobturator male sling for postprostatectomy incontinence: clinical results of a prospective evaluation after a minimum follow-up of 6 months. Eur Urol. 2009;56(6):923–7. Abrams P, Constable LD, Cooper D, MacLennan G, Drake MJ, Harding C, et al. Outcomes of a noninferiority randomised controlled trial of surgery for men with urodynamic stress incontinence after prostate surgery (MASTER). Eur Urol. 2021;79(6):812–23. Kowalik CG, DeLong JM, Mourtzinos AP. The advance transobturator male sling for post-prostatectomy incontinence: subjective and objective outcomes with 3 years follow up. Neurourol Urodyn. 2015;34(3):251–4. Bauer RM, Grabbert MT, Klehr B, Gebhartl P, Gozzi C, Homberg R, et al. 36-month data for the AdVance XP(®) male sling: results of a prospective multicentre study. BJU Int. 2017;119(4):626–30. Article / Publication Details

First-Page Preview

Abstract of Research Article

Received: September 05, 2022
Accepted: December 13, 2022
Published online: February 08, 2023

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 5

ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)

For additional information: https://www.karger.com/UIN

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

留言 (0)

沒有登入
gif